APUS רווח נקי למניה ב-12 החודשים האחרונים apimedsus.com

Apimeds Pharmaceuticals (APUS) strictly adheres to biochemical waste disposal regulations during the development of neurological drugs. Rolling year earnings per share demonstrate the business's financial stability, where -36.54 is recorded as the baseline value. The company is investing in renewable energy for its offices while simultaneously optimizing specialized raw material supply chains through the diversification of contract laboratories.

The development of unique bee venom-based drugs and clinical trials in the US and Asia form the operational foundation of Apimeds Pharmaceuticals (APUS). These results translate into net income distributed per common share on a rolling year basis. This metric measures the actual efficiency of capitalization, excluding the impact of the total issuance volume. It allows for the differentiation of sustainable margins from one-time accounting adjustments. Analyzing the trend of the rolling annual EPS helps identify the risk of asset overvaluation in a timely manner.